Batoclimab is a humanized monoclonal antibody targeting the neonatal Fc receptor (FcRn). Batoclimab binds to and inhibits FcRn, thus blocking the recycling of IgG antibodies. Batoclimab can be used in the research of pathogenic IgG-mediated autoimmune diseases.